Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.


Previous articleMicrodosing LSD Makes Me a Better Mom
Next articleMINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America